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Editorial on the Research Topic
Charged Particles in Oncology
High-energy charged particles represent a cutting-edge technique in radiation oncology (1). 
Protons and carbon ions are used in several centers all over the world for the treatment of different 
solid tumors. Typical indications are ocular malignancies, tumors of the base of the skull, hepato-
cellular carcinomas, and various sarcomas (2). The physical characteristics of the charged particles 
(Bragg peak) allow sparing of much more normal tissues than it is possible using conventional 
X-rays (3), and for this reason, all pediatric tumors are considered eligible for proton therapy (4). 
Ions heavier than protons also display special radiobiological characteristics, which make them 
effective against radioresistant and hypoxic tumors (5).
Protons and ions with high charge (Z) and energy (HZE particles) represent a major risk for 
human space exploration (6, 7). The main late effect of radiation exposure is cancer induction 
(8), and at the moment the dose limits for astronauts are based on lifetime cancer mortality risk 
(9, 10). The Mars Science Laboratory measured the dose on the route to Mars (11) and on the 
planet’s surface (12), supporting predictions that a human exploration mission to Mars will exceed 
the radiation risk limits (7, 13). Notwithstanding many studies on carcinogenesis induced by 
protons and heavy ions, the risk uncertainty remains high with important risk assessment ques-
tions to non-targeted effects (13) and the “quality” of HZE particle-induced tumors compared to 
spontaneous and photon-induced tumors (8).
In this research topic, we invited scientists studying high-energy charged particles either for 
cancer treatment or for space radiation protection. We believe that space radiation protection and 
particle therapy share many common problems, and this research topic can be an inspiration to 
find applications and answers from fields that are apparently far away. Physics, biology, and medical 
contributions in this field will be found in the volume, owing to the fact that the field of charged 
particles in oncology is highly interdisciplinary.
The research topics accepted 59 articles including a total of 351 authors, demonstrating the high 
interest in this field. It is in the top five most viewed research topics of this journal. The articles can 
be divided into the following topics.
PHYSiCS
A number of contributions deal with medical physics in particle therapy. Articles with most views 
are the reviews of range verification methods in particle therapy by Aafke Kraan and of the FLUKA 
Monte Carlo code. FLUKA is widely used at CERN but, from high-energy physics uses, has found 
several applications both in particle therapy and space radiation simulations. Cary Zeitlin and 
Chiara La Tessa describe the role of nuclear fragmentation in particle therapy and space radiation 
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shielding. A highly viewed article by Kim et al. details how nuclear 
fragmentation can be exploited to simulate the full galactic cos-
mic ray spectra using a few particle beams with applications in 
biological countermeasure and radiation shielding studies. Six 
articles deal with experimental methods for range verification 
in particle therapy, using prompt γ-rays, secondary charged 
particles, 4D-PET, or ultrasounds. For space radiation protection, 
the use of active detectors for personal dosimetry is described, 
and potential applications of superconducting magnets for active 
shielding are reported from the SR2S European project.
BioloGY
Several articles deal with experimental radiobiology and 
carcinogenesis induced by high-energy charged particles. In a 
highly viewed article, Sishc et  al. discuss the role of telomeres 
in radiation-induced carcinogenesis. Cellular effects of charged 
particles in comparison to X-rays are reported in tumor cells and 
in normal human endothelial cells. Chromosome aberrations 
and DNA damage response pathways are the main topic of five 
different articles. Specific molecular pathways following exposure 
to charged particles are also described in various articles, e.g., 
transcription factors, prostaglandin (“Phoenix rising” effect), 
bone marrow and mammary cell reprogramming, β-catenin, 
proinflammatory signals.
MEdiCiNE
Twelve manuscripts report clinical results of particle therapy. 
Schiller et  al. review the results of particle therapy in prostate 
cancer, while two articles summarize the Japanese experience 
with carbon ion therapy in Chiba and Gunma. The articles on 
second cancers and late effects after proton therapy are important 
examples of the bridge between therapy and space: the results 
are, in fact, also very important for the assessment of late effects 
caused by cosmic rays in crews of long-term space missions. Lane 
et al. describe results with X-rays using hypofractionation, and 
how high dose/fractionation can be beneficial using protons and 
heavy ions. Modeling clinical results is described in other articles, 
dealing with RBE in proton therapy and combination of particle 
therapy and chemotherapy. An interesting article from Specht 
et al. collects the data on fast neutron therapy and indicates what 
can be learned form that experience in charged particle therapy. 
Fast neutrons are an important risk factor for space missions, too.
FaCilitiES aNd NEtWorKS
Finally, a few articles are dedicated to the analysis of facilities 
for ground-based space research and preclinical radiobiology, 
mini-beams in therapy, and networks and educational activities 
in particle therapy.
The high number of articles submitted, and their excellent 
quality, indicates that the topic is considered of great interest 
for researchers in many different fields. Looking at the overall 
picture, it is clear that space radiation protection and particle 
therapy share many common research problems (14) and can 
learn from each other. Differences are also clear: space radia-
tion protection conditions are whole body, low-dose rate for a 
specialized group of highly skilled workers; radiotherapy is char-
acterized by partial body, high-dose, fractionated exposures of 
cancer patients. Nevertheless, many research topics are similar: 
late effects (see Newhauser et al. in this issue), including cancer 
(see articles by Locke and Weil and Eaton et al. in this issue) and 
tissue degenerative effects such as cardiovascular (15) and CNS 
(16); individual radiosensitivity (see the article by Shim et al. in 
this article); particle and neutron dosimetry (see Schneider and 
Hälg in this issue) and microdosimetry (17); transport calcula-
tions with Monte Carlo (Lima et al. in this issue) and analytical 
codes; radioprotectors; and non-targeted effects (see the article by 
Barcellos-Hoff and Mao in this issue). They also share common 
platforms for research. We hope that this ebook will be useful for 
researchers working on charged particles in looking for answers 
to the many questions that these two topics, only apparently far 
away, share.
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